Friday, March 31, 2023
Clinical Advances in
Read Overview
Supported by an independent educational grant from Bayer
Steering Committee Member
Professor of Pathology
Head of the Department of Pathology and Tumor Biology
Chief Executive Officer
Jean Perrin Comprehensive Cancer Center
Clermont-Ferrand, Franceâ
Steering Committee Member
Professor of Medicine
Harvard Medical School
Director
Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts, United Statesâ
Steering Committee Member
Director
Division of Hematology, Oncology and
Transplantation
Masonic Cancer Center
University of Minnesota
Minneapolis, Minnesota, United Statesâ
Steering Committee Member
Professor and Deputy Chair
The University of Texas MD Anderson Cancer Center
Houston, Texas, United Statesâ
Steering Committee Member
Clinical Director
Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York, United Statesâ
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer; Illumina; Nanostring; Roche; Roche Diagnostics
Received grants for clinical research from: Bayer; Roche
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; AdaptImmune; Bayer; Blueprint Medicines; C4 Therapeutics; Daiichi-Sankyo; EMD-Serono/Merck KGaA; Epizyme; GlaxoSmithKline; ICON; Janssen; LOXO Oncology; McCann Health; Mirati; MJ Hennessey/OncLive; Novartis; Pfizer; PharmaMar; Polaris; Roche/Genentech; Sanofi; Synlogic; Translate BIO; WCG/Arsenal Capital
Received grants for clinical research from: AbbVie; AdaptImmune; Bayer; Daiichi-Sankyo; Epizyme; GlaxoSmithKline; LOXO Oncology; Janssen; Novartis; Pfizer; PharmaMar; Roche/Genentech
Owns stock, stock options, or bonds from: G1 Therapeutics; Bessor Pharmaceuticals; Blueprnt Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Biotechnology; Erasca Pharmaceuticals; G1 Therapeutics; RELAY Therapeutics; Translate BIO
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer; Bristol Myers Squibb; Myovant; Riovant
Received grants for clinical research from: Clovis Oncology; Pfizer; Sanofi-Genzyme
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alpha Insights; Acuta; Amgen; Axiom; AdaptImmune; Baxter; Bayer; Boxer Capital; COG; ECOR1; Expert Connect; Genentech; GLG; Group H; Guidepoint; H. C. Wainwright; Infinity; Janssen; Merrimack; NTRK Connect; Numab; Pfizer; Prime Oncology; Seattle Genetics; SlingShot; Takeda; Trieza Therapeutics
Received grants for clinical research from: AbbVie; AdaptImmune; Aldo-Norte; Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Daiichi-Sankyo; Eisai; Fate Therapeutics; Genentech; Genmab; Ignyta; Infinity; Kite; Kyowa; Lilly; LOXO Oncology; Merck; MedImmune; Mirati; miRNA; Molecular Templates; Mologen; NCI-CTEP; Novartis; Numab; Pfizer; Seattle Genetics; Takeda; Turning Point Therapeutics; Verstatem
Other: Travel, accommodations, expenses: Bayer; LOXO Oncology; miRNA; Genmab; AACR; ASCO; SITC; Ownership interests: Molecular Match; OncoResponse; Presagia
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: 14ner/Elevation Oncology; AbbVie; ArcherDX; AstraZeneca; Beigene; BergenBio; Blueprint Medicines; EMD Serono; Exelixis; Helsinn; Hengrui Therapeutics; Ignyta/Genentech/Roche; LOXO/Bayer/Lilly; Melendi; Monopteros; MORE Health; Novartis; Pfizer; Remedica Ltd; Takeda/Ariad/Millenium; TP Therapeutics; Tyra Biosciences; Verastem
Received grants for clinical research from: Exelixis; Foundation Medicine; GlaxoSmithKline; Pfizer; PharmaMar; Taiho; Teva
Other: Royalties: Wolters Kluwer; Expenses: Boehringer Ingelheim; Merck; Merus; Puma
Podcast Series: Emerging Practice Patterns in Clinical Oncology 2020
Listen to Podcasts